Taysha Gene Therapies (TSHA) Change in Account Payables (2020 - 2026)

Taysha Gene Therapies has disclosed Change in Account Payables across 7 years of filings, most recently posting $1.3 million for Q1 2026.

• Change in Account Payables for Q1 2026 came in at $1.3 million, up 39.65% year-over-year; the trailing twelve-month figure through Mar 2026 was $213000.0 (up 103.56% YoY), and the FY2025 annual result was -$153000.0, up 94.76% from the prior year.
• Change in Account Payables came in at $1.3 million for Q1 2026 at Taysha Gene Therapies, up from -$2.1 million in the prior quarter.
• In the past five years, Change in Account Payables ranged from a high of $4.0 million in Q1 2024 to a low of -$9.4 million in Q3 2022.
• The 5-year median for Change in Account Payables is -$1.2 million (2023), against an average of -$699000.0.
• Peak annual rise in Change in Account Payables reached 1008.64% in 2024, while the deepest fall reached 191.55% in 2024.
• Taysha Gene Therapies' Change in Account Payables stood at -$4.6 million in 2022, then soared by 73.19% to -$1.2 million in 2023, then slipped by 22.28% to -$1.5 million in 2024, then tumbled by 41.36% to -$2.1 million in 2025, then surged by 160.63% to $1.3 million in 2026.
• The last three Change in Account Payables figures came in at $1.3 million (Q1 2026), -$2.1 million (Q4 2025), and -$1.9 million (Q3 2025), per Business Quant data.